Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine
2. Gs-9973
1. 1229208-44-9
2. Gs-9973
3. 6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine
4. Entospletinib [inn]
5. Entospletinib (gs-9973)
6. Gs9973
7. 6i3o3w6o3b
8. Chembl3265032
9. Syk Inhibitor Gs-9973
10. 6-(1h-indazol-6-yl)-n-(4-(morpholin-4-yl)phenyl)imidazo(1,2-a)pyrazin-8-amine
11. Imidazo(1,2-a)pyrazin-8-amine, 6-(1h-indazol-6-yl)-n-(4-(4-morpholinyl)phenyl)-
12. 6-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
13. 6-(1h-indazol-6-yl)-n-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine
14. Entospletinib [usan:inn]
15. Unii-6i3o3w6o3b
16. 4puz
17. Imidazo[1,2-a]pyrazin-8-amine, 6-(1h-indazol-6-yl)-n-[4-(4-morpholinyl)phenyl]-
18. Gs 9973
19. Gs9973entospletinib
20. Gs-9973; Entospletinib
21. Entospletinib (usan/inn)
22. Entospletinib [usan]
23. Entospletinib [who-dd]
24. Gtpl7889
25. Schembl2483776
26. Dtxsid001317670
27. Hms3653d13
28. Hms3673e05
29. Hms3750e13
30. Amy14224
31. Bcp09582
32. Ex-a1120
33. Bdbm50015448
34. Mfcd28099806
35. Nsc781516
36. Nsc800988
37. S7523
38. Zinc98208742
39. Akos027295322
40. Ccg-264700
41. Db12121
42. Nsc-781516
43. Nsc-800988
44. Sb16830
45. Ncgc00378596-07
46. Ac-30236
47. As-17026
48. Da-36929
49. Hy-15968
50. Ft-0700130
51. Sw220048-1
52. D11209
53. A890877
54. J-690079
55. Q27077193
56. Entospletinib;6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine
57. 6-cyclopropyl-8-fluoro-2-[2-(hydroxymethyl)-3-(1-methyl-5-{[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino}-6-oxo-1,6-dihydro-3-pyridi Nyl)phenyl]-1(2h)-isoquinolinone
| Molecular Weight | 411.5 g/mol |
|---|---|
| Molecular Formula | C23H21N7O |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 4 |
| Exact Mass | 411.18075832 g/mol |
| Monoisotopic Mass | 411.18075832 g/mol |
| Topological Polar Surface Area | 83.4 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 595 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of acute myeloid leukaemia
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Entospletinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Entospletinib, including repackagers and relabelers. The FDA regulates Entospletinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Entospletinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Entospletinib supplier is an individual or a company that provides Entospletinib active pharmaceutical ingredient (API) or Entospletinib finished formulations upon request. The Entospletinib suppliers may include Entospletinib API manufacturers, exporters, distributors and traders.
Entospletinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Entospletinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Entospletinib GMP manufacturer or Entospletinib GMP API supplier for your needs.
A Entospletinib CoA (Certificate of Analysis) is a formal document that attests to Entospletinib's compliance with Entospletinib specifications and serves as a tool for batch-level quality control.
Entospletinib CoA mostly includes findings from lab analyses of a specific batch. For each Entospletinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Entospletinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Entospletinib EP), Entospletinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Entospletinib USP).
LOOKING FOR A SUPPLIER?
